SCHEMBL15904002

SCHEMBL15904002

CC(=O)NCc1cc(-c2cc[c]cc2)no1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.71
SMN1; SMN2 Q16637 4/20 0.68
CYP1A2 P05177 2/20 0.68
LMNA P02545 4/20 0.53
ALDH1A1 P00352 4/20 0.52
HTT P42858 4/20 0.52
JAK2 O60674 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
HPGD P15428 2/20 0.47
MAPT P10636 3/20 0.44
EPHX2 P34913 2/20 0.44
RXFP1 Q9HBX9 1/20 0.43
NOTUM Q6P988 2/20 0.41
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15904035 0.86 POLB (0.54) POLBSMN1; SMN2CYP1A2LMNAALDH1A1
SCHEMBL23451628 0.86 POLB (0.75) POLBSMN1; SMN2CYP1A2LMNAALDH1A1
SCHEMBL17469084 0.83 POLB (1.00) POLBSMN1; SMN2CYP1A2LMNAALDH1A1
SCHEMBL3591952 0.78 POLB (0.72) POLBSMN1; SMN2CYP1A2LMNAALDH1A1
SCHEMBL15904333 0.78 MAPT (0.52) POLBSMN1; SMN2CYP1A2LMNAALDH1A1
SCHEMBL15904092 0.76 NOTUM (0.69) POLBSMN1; SMN2CYP1A2LMNAALDH1A1
SCHEMBL17313778 0.75 MAPT (0.44) POLBSMN1; SMN2CYP1A2LMNAALDH1A1
SCHEMBL6401623 0.74 NOTUM (0.61) POLBSMN1; SMN2CYP1A2LMNAALDH1A1
SCHEMBL4664040 0.72 POLB (0.56) POLBSMN1; SMN2CYP1A2ALDH1A1EPHX2
SCHEMBL6408141 0.72 POLB (0.56) POLBSMN1; SMN2CYP1A2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
EP-2948450-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals, Inc. (US) 2015-12-02 EP disclosed
WO-2014117090-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO POLB 1777/4885SMN1; SMN2 1142/4885CYP1A2 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.